Shanghai Immuxell Biotech Launches Phase I Clinical Trial of IX001 TCR-T Injection, a First-in-Class Therapy Targeting KRAS G12V for Advanced Pancreatic Cancer

Dr. Hu Hongming, founder of ImmuXell Biotech, said:TCR-TThe therapy has unique advantages in the treatment of solid tumors, capable of targeting intracellular antigens that traditional antibody drugs cannot reach. The successful initiation of the Phase I clinical trial is an important milestone in the company's development, marking another critical step in our transition from laboratory to clinical application. By advancing the Phase I clinical trial, we aim to gather more safety and efficacy data for the therapeutic products, and we look forward to "IX001 TCR-TThe injection solution will benefit the subjects sooner, bringing innovation and breakthroughs to pancreatic cancer tumor treatment — "With the strength of ImmuXell Biotech, safeguarding the resilience of life."

We would like to thank the investigators, partners, participants, and their families involved in the clinical trials. We will accelerate the development of cancer treatments. Meanwhile, ImmuXell Biotech remains committed to continuous independent research and development.TCR-TIn the field of cell therapy, we have multiple product pipelines in progress, and we hope to bring more products to clinical trials in the future, providing efficient and safe treatment options for more patients with solid tumors.

About ImmuXell: ImmuXell Biotech LtD. (hereinafter referred to as "ImmuXell Biotech") was established2021Year, a company focused on solid tumorsTCR-T A biotechnology company in the clinical stage of cell therapy. ImmuXell Biotech focuses on independently discovering and identifying tumor gene mutations (KRAS) ofTCR`, and promote`TCR-TTechnical Optimization and Clinical Application of Cell Therapy. CompanyIITClinical studies have shownTCR-TThe preliminary efficacy and safety of cell therapy have shownTCR-TThe Great Potential of Cell Therapy in Solid Tumor Treatment. ImmuXell Biotech LtD., based in Shanghai, has an efficient R&D team capable of rapidly and effectively translating fundamental laboratory discoveries into clinical applications. Since its establishment, the company has filed multiple patents related to its core business, been selected as a "National Science and Technology Small and Medium-sized Enterprise," and, as a sub-project leader, received2023Annual National Key R&D Program "Frontier Biotechnology" Joint Application Project, participated as a corporate partner.2025YearNational Health Commission Major Special Project "Systemic Treatment Strategy for Liver Cancer Based on Individualized Precision AssessmentClinical Research”。ImmuXell Biotech will adhere to the development philosophy of "innovation, cooperation, and win-win," collaborate with global partners in the biopharmaceutical field, jointly promote the innovation and development of tumor cell immunotherapy technologies, extend the survival period of patients with relapsed and refractory tumors, and achieve clinical benefits.